

October 23, 2018



BioCorRx Inc.'s CEO Talks NIDA Grant Update and a Promising New Product with Uptick Newswire's Stock Day Podcast

PHOENIX, Oct. 23, 2018 (GLOBE NEWSWIRE) -- **BioCorRx Inc. (OTCQB: [BICX](#))** (the "**Company**") is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President, CEO, and Director of BioCorRx Inc, Brady Granier talked with Stock Day's Everett Jolly about exciting developments at the company.

Jolly asked for a general explanation of what it is that BioCorRx Inc. does to help fight addiction.

"We do several things in the space," explained Granier. "We have a behavioral program that was developed by addiction experts that includes cognitive behavioral therapy. This helps people move ahead once they are in therapy."

He went on to explain how the company's naltrexone implant is specifically formulated with completely biodegradable pellets that are typically inserted just beneath the skin in the lower abdominal area. The behavioral program and the naltrexone implant are combined with peer support to make up their multi-pronged program to help combat substance use disorder.

Jolly then asked Granier for an update on the grant submitted to The National Institute on Drug Abuse (NIDA) for BICX102. BICX102 is the Company's sustained release naltrexone implant for the treatment of alcohol and opioid use disorders. Granier explained that the company received a Just-In-Time (JIT) request from NIDA earlier in the month, which they believe is a good sign.

"We're in the process of compiling information they requested," he said. He then went on to explain that they expect to know the outcome sometime around mid-November.

Jolly then turned the conversation to a recent letter of intent with VDM Biochemicals, Inc. Under the agreement, BioCorRx has the right of first refusal to acquire up to a 49% ownership stake in VDM-001. VDM-001 may represent an effective alternative to naloxone in the overdose reversal market.

Granier explained that they need to ultimately validate the product once a definitive agreement is reached. He went on to say they need to do their own studies on the product and if it works as VDM Biochemicals, Inc. claims, Granier believes it could be a promising product.

To hear more about what BioCorRx Inc. has to offer listen to the full podcast here: <https://upticknewswire.com/featured-interview-ceo-brady-granier-of-biocorr-x-inc-otcqb-bicx-3/>

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

Contact:

BioCorRx Inc.
investors@BioCorRx.com
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

About Uptick Newswire and the “Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at <https://investorshangout.com/>

SOURCE:
Uptick Newswire
<https://upticknewswire.com/>

Source: BioCorRx Inc.